Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2017

Open Access 01-12-2017 | Research

Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1)

Authors: Yixue Gu, Zhijie Zhang, Jiang Yin, Jiahui Ye, Yin Song, Hao Liu, Yan Xiong, Minying Lu, Guopei Zheng, Zhimin He

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Login to get access

Abstract

Background

The potential mechanisms regarding how methylation of microRNA(miRNA) CpG Island could regulate cancer cell chemo-resistance remains unclear. This study aims to explore the epigenetic dysregulation mechanism of miRNA-493 and the ability to modulate lung cancer cell chemotherapy resistance.

Methods

Real-time quantitative PCR (qRT-PCR) and In situ hybridization (ISH) were used to analyze the expression of miR-493 in lung cancer cell lines and tumor tissue, respectively. Bisulfite sequencing PCR (BSP) was used to exam the promoter CpG Island of miR-493. The effect of miR-493 on chemosensitivity was evaluated by cell viability assays, apoptosis assays and in vivo experiment. The DNA damage was measured by γ-H2AX immunofluorescence. Luciferase reporter assay was used to assess the target genes of miR-493. Expression of target proteins and downstream molecules were analyzed by Western blot.

Results

miR-493 is silenced in resistant lung cancer cell due to the aberrant DNA methylation. Enforced expression of miR-493 in lung cancer cells promotes chemotherapy sensitivity to cisplatin through impairing the DNA damage repair and increasing the cells apoptosis in vitro and in vivo. Furthermore, we identify that TCRP1 is a direct functional target of miR-493. Ectopic expression of TCRP1 attenuated increased apoptosis in miR-493-overexpressing lung cancer cells upon cisplatin treatment. Meanwhile, miR-493 level is negatively correlated with TCRP1 expression in lung cancer patients and TCRP1 expression were correlated with poor survival.

Conclusions

Our results highlight that hyper-methylation of miR-493CpG island might play important roles in the development of lung cancer chemo-resistance by targeting TCRP1, which might be used as a potential therapeutic target in preventing the chemo-resistance of lung cancer.
Literature
1.
go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed
2.
go back to reference Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol. 2009;220(3):538–47.CrossRefPubMed Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol. 2009;220(3):538–47.CrossRefPubMed
3.
go back to reference Van Den Broeck A, Ozenne P, Eymin B, Gazzeri S. Lung cancer: a modified epigenome. Cell Adhes Migr. 2010;4(1):107–13.CrossRef Van Den Broeck A, Ozenne P, Eymin B, Gazzeri S. Lung cancer: a modified epigenome. Cell Adhes Migr. 2010;4(1):107–13.CrossRef
4.
go back to reference Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61(1):249–55.PubMed Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61(1):249–55.PubMed
5.
go back to reference Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95(20):11891–6.CrossRefPubMedPubMedCentral Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95(20):11891–6.CrossRefPubMedPubMedCentral
6.
go back to reference Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest. 2003;111(6):887–95.CrossRefPubMedPubMedCentral Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest. 2003;111(6):887–95.CrossRefPubMedPubMedCentral
7.
go back to reference Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest. 2013;123(12):5231–46.CrossRefPubMedPubMedCentral Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest. 2013;123(12):5231–46.CrossRefPubMedPubMedCentral
8.
go back to reference Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M. Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci. 2013;14(10):21087–113.CrossRefPubMedPubMedCentral Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M. Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci. 2013;14(10):21087–113.CrossRefPubMedPubMedCentral
9.
go back to reference Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics. 2011;3(1):83–92.CrossRefPubMed Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics. 2011;3(1):83–92.CrossRefPubMed
10.
11.
go back to reference Xi S, Xu H, Shan J, Tao Y, Hong JA, Inchauste S, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest. 2013;123(3):1241–61.CrossRefPubMedPubMedCentral Xi S, Xu H, Shan J, Tao Y, Hong JA, Inchauste S, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest. 2013;123(3):1241–61.CrossRefPubMedPubMedCentral
12.
go back to reference Okamoto K, Ishiguro T, Midorikawa Y, Ohata H, Izumiya M, Tsuchiya N, et al. miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver. EMBO J. 2012;31(7):1752–63.CrossRefPubMedPubMedCentral Okamoto K, Ishiguro T, Midorikawa Y, Ohata H, Izumiya M, Tsuchiya N, et al. miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver. EMBO J. 2012;31(7):1752–63.CrossRefPubMedPubMedCentral
13.
go back to reference Ueno K, Hirata H, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, et al. Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer Ther. 2012;11(1):244–53.CrossRefPubMed Ueno K, Hirata H, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, et al. Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer Ther. 2012;11(1):244–53.CrossRefPubMed
14.
go back to reference Sakai H, Sato A, Aihara Y, Ikarashi Y, Midorikawa Y, Kracht M, et al. MKK7 mediates miR-493-dependent suppression of liver metastasis of colon cancer cells. Cancer Sci. 2014;105(4):425–30.CrossRefPubMedPubMedCentral Sakai H, Sato A, Aihara Y, Ikarashi Y, Midorikawa Y, Kracht M, et al. MKK7 mediates miR-493-dependent suppression of liver metastasis of colon cancer cells. Cancer Sci. 2014;105(4):425–30.CrossRefPubMedPubMedCentral
15.
go back to reference Gu Y, Cheng Y, Song Y, Zhang Z, Deng M, Wang C, et al. MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1. PLoS One. 2014;9(8):e102602.CrossRefPubMedPubMedCentral Gu Y, Cheng Y, Song Y, Zhang Z, Deng M, Wang C, et al. MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1. PLoS One. 2014;9(8):e102602.CrossRefPubMedPubMedCentral
16.
go back to reference Gu Y, Fan S, Xiong Y, Peng B, Zheng G, Yu Y, et al. Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. FEBS Lett. 2011;585(6):881–7.CrossRefPubMed Gu Y, Fan S, Xiong Y, Peng B, Zheng G, Yu Y, et al. Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. FEBS Lett. 2011;585(6):881–7.CrossRefPubMed
17.
go back to reference Peng B, Gu Y, Xiong Y, Zheng G, He Z. Microarray-assisted pathway analysis identifies MT1X & NFkappaB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma. PLoS One. 2012;7(12):e51413.CrossRefPubMedPubMedCentral Peng B, Gu Y, Xiong Y, Zheng G, He Z. Microarray-assisted pathway analysis identifies MT1X & NFkappaB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma. PLoS One. 2012;7(12):e51413.CrossRefPubMedPubMedCentral
18.
go back to reference Liu X, Wang C, Gu Y, Zhang Z, Zheng G, He Z. TCRP1 contributes to cisplatin resistance by preventing Pol beta degradation in lung cancer cells. Mol Cell Biochem. 2015;398(1-2):175–83.CrossRefPubMed Liu X, Wang C, Gu Y, Zhang Z, Zheng G, He Z. TCRP1 contributes to cisplatin resistance by preventing Pol beta degradation in lung cancer cells. Mol Cell Biochem. 2015;398(1-2):175–83.CrossRefPubMed
19.
go back to reference Liu X, Feng M, Zheng G, Gu Y, Wang C, He Z. TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncol Lett. 2017;13(3):1398–405.PubMed Liu X, Feng M, Zheng G, Gu Y, Wang C, He Z. TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncol Lett. 2017;13(3):1398–405.PubMed
20.
go back to reference Olive PL, Banath JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom. 2009;76(2):79–90.CrossRefPubMed Olive PL, Banath JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom. 2009;76(2):79–90.CrossRefPubMed
21.
go back to reference Gu Y, Fan S, Liu B, Zheng G, Yu Y, Ouyang Y, He Z. TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway. Mol Cell Biochem. 2011;357(1-2):107–13.CrossRefPubMed Gu Y, Fan S, Liu B, Zheng G, Yu Y, Ouyang Y, He Z. TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway. Mol Cell Biochem. 2011;357(1-2):107–13.CrossRefPubMed
22.
go back to reference Wang C, Liu H, Qiu Q, Zhang Z, Gu Y, He Z. TCRP1 promotes NIH/3T3 cell transformation by over-activating PDK1 and AKT1. Oncogene. 2017;6(4):e323.CrossRef Wang C, Liu H, Qiu Q, Zhang Z, Gu Y, He Z. TCRP1 promotes NIH/3T3 cell transformation by over-activating PDK1 and AKT1. Oncogene. 2017;6(4):e323.CrossRef
23.
go back to reference Lv JF, Hu L, Zhuo W, Zhang CM, Zhou HH, Fan L. Epigenetic alternations and cancer chemotherapy response. Cancer Chemother Pharmacol. 2016;77(4):673–84.CrossRefPubMed Lv JF, Hu L, Zhuo W, Zhang CM, Zhou HH, Fan L. Epigenetic alternations and cancer chemotherapy response. Cancer Chemother Pharmacol. 2016;77(4):673–84.CrossRefPubMed
24.
go back to reference Harada K, Baba Y, Ishimoto T, Kosumi K, Tokunaga R, Izumi D, et al. Suppressor microRNA-145 is epigenetically regulated by promoter Hypermethylation in esophageal Squamous cell carcinoma. Anticancer Res. 2015;35(9):4617–24.PubMed Harada K, Baba Y, Ishimoto T, Kosumi K, Tokunaga R, Izumi D, et al. Suppressor microRNA-145 is epigenetically regulated by promoter Hypermethylation in esophageal Squamous cell carcinoma. Anticancer Res. 2015;35(9):4617–24.PubMed
25.
go back to reference Wang S, Zhang R, Claret FX, Yang H. Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. Mol Cancer Ther. 2014;13(12):3163–74.CrossRefPubMedPubMedCentral Wang S, Zhang R, Claret FX, Yang H. Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. Mol Cancer Ther. 2014;13(12):3163–74.CrossRefPubMedPubMedCentral
26.
go back to reference Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014;342(2):200–12.CrossRefPubMed Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014;342(2):200–12.CrossRefPubMed
28.
go back to reference Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009;8(6):1409–20.CrossRefPubMed Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009;8(6):1409–20.CrossRefPubMed
29.
go back to reference Toll A, Salgado R, Espinet B, Diaz-Lagares A, Hernandez-Ruiz E, Andrades E, et al. MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression. Mol Cancer. 2016;15(1):53.CrossRefPubMedPubMedCentral Toll A, Salgado R, Espinet B, Diaz-Lagares A, Hernandez-Ruiz E, Andrades E, et al. MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression. Mol Cancer. 2016;15(1):53.CrossRefPubMedPubMedCentral
30.
go back to reference Kim YH, Lee WK, Lee EB, Son JW, Kim DS, Park JY. Combined Effect of Metastasis-Related MicroRNA, miR-34 and miR-124 Family, Methylation on Prognosis of Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016;18(1):e13–e20. Kim YH, Lee WK, Lee EB, Son JW, Kim DS, Park JY. Combined Effect of Metastasis-Related MicroRNA, miR-34 and miR-124 Family, Methylation on Prognosis of Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016;18(1):e13–e20.
31.
go back to reference Tellez CS, Juri DE, Do K, Picchi MA, Wang T, Liu G, et al. miR-196b is epigenetically silenced during the premalignant stage of lung carcinogenesis. Cancer Res. 2016;76(16):4741–51.CrossRefPubMedPubMedCentral Tellez CS, Juri DE, Do K, Picchi MA, Wang T, Liu G, et al. miR-196b is epigenetically silenced during the premalignant stage of lung carcinogenesis. Cancer Res. 2016;76(16):4741–51.CrossRefPubMedPubMedCentral
32.
go back to reference Zhao L, Feng X, Song X, Zhou H, Zhao Y, Cheng L, Jia L. miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4. Oncol Rep. 2016;36(2):1007–15.CrossRefPubMed Zhao L, Feng X, Song X, Zhou H, Zhao Y, Cheng L, Jia L. miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4. Oncol Rep. 2016;36(2):1007–15.CrossRefPubMed
33.
go back to reference Tambe M, Pruikkonen S, Maki-Jouppila J, Chen P, Elgaaen BV, Straume AH, et al. Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel. Oncotarget. 2016;7(11):12267–85.CrossRefPubMedPubMedCentral Tambe M, Pruikkonen S, Maki-Jouppila J, Chen P, Elgaaen BV, Straume AH, et al. Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel. Oncotarget. 2016;7(11):12267–85.CrossRefPubMedPubMedCentral
Metadata
Title
Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1)
Authors
Yixue Gu
Zhijie Zhang
Jiang Yin
Jiahui Ye
Yin Song
Hao Liu
Yan Xiong
Minying Lu
Guopei Zheng
Zhimin He
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-017-0582-5

Other articles of this Issue 1/2017

Journal of Experimental & Clinical Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine